Report ID: 10151856 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Nanotechnology provides better safety for highly toxic drugs. The application of nanotechnology in medicine, especially drug delivery, is expected to increase rapidly. When formulating injectable nanomedicines, various strategies can be used to improve drug delivery and efficacy, for example. For example, it allows a higher level of treatment at the target site at a lower dose. The injectable nanomedicine delivers the drug to the target site and allows the drug to accumulate at the site of action. Bing and ligands improve the therapeutic effect of injectable nanomedicine and enhance active targeting. Better disease management through selective drug delivery is expected to lead to an increase in the demand for injectable nanomedicine.The technological advancement of liposomal drug delivery systems is conducive to the development of injectable nanomedicine:
The design and shape of nanoparticles have been greatly promoted in research, which has led to the development of better injectable nanomedicine. For example, major drug manufacturers are currently using liposome technology to deliver sustained-release drugs and reduce dosages. These include DepoFoamTM technology, non-pegylation technology (NPL), etc. These technologies improve patient compliance with medications by reducing dosage and reducing side effects. In addition, the rapid adoption of new and complex technologies to develop non-replicable drugs to maintain competition is a factor that is expected to support the revenue growth of the injectable nanomedicine market during the forecast period.The technological advancement of liposomal drug delivery systems is conducive to the development of injectable nanomedicine:
The design and shape of nanoparticles have been greatly promoted in research, which has led to the development of better injectable nanomedicine. For example, major drug manufacturers are currently using liposome technology to deliver sustained-release drugs and reduce dosages. These include DepoFoamTM technology, non-pegylation technology (NPL), etc. These technologies improve patient compliance with medications by reducing dosage and reducing side effects. In addition, the rapid adoption of new and complex technologies to develop non-replicable drugs to maintain competition is a factor that is expected to support the revenue growth of the injectable nanomedicine market during the forecast period.The technological advancement of liposomal drug delivery systems is conducive to the development of injectable nanomedicine:
The design and shape of nanoparticles have been greatly promoted in research, which has led to the development of better injectable nanomedicine. For example, major drug manufacturers are currently using liposome technology to deliver sustained-release drugs and reduce dosages. These include DepoFoamTM technology, non-pegylation technology (NPL), etc. These technologies improve patient compliance with medications by reducing dosage and reducing side effects. In addition, the rapid adoption of new and complex technologies to develop non-replicable drugs to maintain competition is a factor that is expected to support the revenue growth of the injectable nanomedicine market during the forecast period.The increase in nanomedicine development funds is expected to drive the growth of the injectable nanomedicine market:
The government's steady increase in funding for nanomedicine development attracts more marketing and development interest from drug manufacturers, which makes the market more competitive. In this regard, the US federal authorities have provided US$1.4 billion in funding within the framework of the National Nanotechnology Initiative, reflecting the growing importance and interest in nanomedicine. Increasing use of nanomedicine in drug discovery is the main factor that is expected to drive the revenue growth of the global injectable nanomedicine market during the forecast period.
Competitive landscape:
The competition section of the report introduces an overview of the main players operating in the injectable nanomedicine market based on market share, product supply, and differentiated product marketing strategies. Several major players listed in the injectable nanomedicine market report include Merck KGaA, Amgen, Pfizer, Lupin, Janssen Biotechnology, Hoffman La Roche, Teva Pharmaceutical Industries Co., Ltd., Pa Syrah Pharmaceuticals, New Foundation and Bausch & Lomb.
These companies offer a wide range of injectable nanomedicines. Emerging players operating in the injectable nanomedicine market are mainly focused on new marketing strategies to expand their product share in the global injectable nanomedicine market. Major players in the injection nanomedicine market are investing in research and development to develop innovative nanomedicines. There are currently several injectable nanomedicines undergoing clinical trials and are expected to be launched in recent years, which may increase competition in the injectable nanomedicine market.
Definition:
Nanomedicine is a drug or biological agent containing 10-1000 nm nanoparticles to achieve site specificity, reduce toxicity, or improve the efficacy of in vivo imaging or therapeutic agents. The composition and form of nanomedicine are diverse. Nanomedicine is likely to be a complex combination product. In most cases, through oral or intravenous injection, the injectable nanomedicine is a purer soluble formulation that can deliver the drug in a smaller volume.
Segmentation:
The report provides a complete breakdown of the injectable nanomedicine market by drug type, application, end user, and region. According to the type of drug, the global injectable nanomedicine market has been subdivided into liposomes, micelles, nanocrystals, polymer nanoparticles, metal nanoparticles, and mesoporous silica nanoparticles. According to the application, the global injectable nanomedicine market has been subdivided into cancer, central nervous system diseases, cardiovascular diseases, infection control, inflammatory diseases, etc. On the basis of end users, the global injectable nanomedicine market has been subdivided into hospitals, outpatient surgery centers, clinics, professional drug research and development institutions, and managed medical institutions. From a geographic perspective, the injectable nanomedicine market has been subdivided into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa (MEA)
Research method:
The market for injectable nanomedicine has been estimated based on the supply and demand method. The triangulation method is used to derive the market size of injectable nanomedicine, which is mainly based on the total expenditure based on disease epidemiology, life science research and R&D funds to obtain accurate market data and life science-related services, products and services Knowledge and biotechnology. Technology and application. This information is further verified through rigorous primary research (including interviews, surveys, face-to-face interactions and insights from experienced analysts) and secondary research (including verified paid sources, authentic trade journals, and resource-rich databases).
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10151856 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
